Dexrazoxane for the treatment of chemotherapy-related side effects

References

• HasinoffBBKuschakTIYalowichJCCreightonAMA QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane)Biochem Pharmacol19955079539587575679
   PubMed Web of Science ®Google Scholar
• NitissJLTargeting DNA topoisomerase II in cancer chemotherapyNat Rev Cancer20099533835019377506
   PubMed Web of Science ®Google Scholar
• GeigyJR UK Patent 978,7241964
   Google Scholar
• Eastman Kodak Co UK Patent 1,001,1571965
   Google Scholar
• CreightonAMHellmannKWhitecrossSAntitumour activity in a series of bisdiketopiperazinesNature196922251913843855782118
   PubMed Web of Science ®Google Scholar
• HellmannKNewtonKAWhitmoreDNHanhamIWBondJVPreliminary clinical assessment of ICRF 159 in acute leukaemia and lymphosarcomaBr Med J1969156478228245251696
   PubMed Web of Science ®Google Scholar
• HermanEHMhatreRMChadwickDPModification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943)Toxicol Appl Pharmacol1974275175264212173
   PubMed Web of Science ®Google Scholar
• HermanEHArdalanBBierCWaravdekarVKropSReduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamstersCancer Treat Rep1979638992421236
   PubMedGoogle Scholar
• HermanEHFerransVJInfluence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swineLab Invest198349169776408310
   PubMed Web of Science ®Google Scholar
• HermanEHFerransVJYoungRSHamlinRLPretreatment with ICRF-187 allows a marked increase in the total cumulative dose of doxorubicin tolerated by beagle dogsDrugs Exp Clin Res19881495635703147886
   PubMedGoogle Scholar
• HermanEHFerransVJPreclinical animal models of cardiac protection from anthracycline-induced cardiotoxicitySemin Oncol1998254 Suppl 1015219768819
   PubMed Web of Science ®Google Scholar
• LangerSWSehestedMJensenPBTreatment of anthracycline extravasation with dexrazoxaneClin Cancer Res200093680368610999761
   PubMed Web of Science ®Google Scholar
• LangerSWSehestedMJensenPBDexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in miceAnn Oncol200112340541011332155
   PubMed Web of Science ®Google Scholar
• LangerSWThougaardAVSehestedMJensenPBTreatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisoneCancer Chemother Pharmacol200657112512816001176
   PubMed Web of Science ®Google Scholar
• ThougaardAVLangerSWHainauBA murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damageToxicology20102691677220079798
   PubMed Web of Science ®Google Scholar
• LangerSWExtravasation reactionsLacoutureMEDermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer PatientsJohn Wiley & Sons IncHoboken, New Jersey2014295300
   Google Scholar
• GewirtzDAA critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochem Pharmacol199957772774110075079
   PubMed Web of Science ®Google Scholar
• FortuneJMOsheroffNTopoisomerase II as a target for anticancer drugs: when enzymes stop being niceProg Nucleic Acid Res Mol Biol20006422125310697411
   PubMed Web of Science ®Google Scholar
• HasinoffBBHellmannKHermanEHFerransVJChemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazinesCurr Med Chem1998511289481032
   PubMed Web of Science ®Google Scholar
• ForceTIntroduction to cardiotoxicity review seriesCirc Res20101061192020056942
   PubMed Web of Science ®Google Scholar
• YoussefGLinksMThe prevention and management of cardiovascular complications of chemotherapy in patients with cancerAm J Cardiovasc Drugs2005523324315984906
   PubMedGoogle Scholar
• HasinoffBBDaveyJPAdriamycin and its iron(III) and copper(II) complexes. Glutathione-induced dissociation; cytochrome c oxidase inactivation and protection; binding to cardiolipinBiochem Pharmacol19883719366336692845993
   PubMed Web of Science ®Google Scholar
• De AngelisAPiegariECappettaDAnthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell functionCirculation2010121227629220038740
   PubMed Web of Science ®Google Scholar
• FerransVJClarkJRZhangJYuZXHermanEHPathogenesis and prevention of doxorubicin cardiomyopathyTsitologiia199739109289379505340
   PubMedGoogle Scholar
• Von HoffDDRozencweigMLayardMSlavikMMuggiaFMDaunomycin-induced cardiotoxicity in children and adults. A review of 110 casesAm J Med1977622200208835599
   PubMed Web of Science ®Google Scholar
• LipshultzSEColanSDGelberRDPerez-AtaydeARSallanSESandersSPLate cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhoodN Engl J Med1991324128088151997853
   PubMed Web of Science ®Google Scholar
• KremerLCvan DalenECOffringaMOttenkampJVoûtePAAnthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up studyJ Clin Oncol200119119119611134212
   PubMed Web of Science ®Google Scholar
• NielsenDJensenJBDombernowskyPEpirubicin cardiotoxicity: a study of 135 patients with advanced breast cancerJ Clin Oncol1990811180618102230869
   PubMed Web of Science ®Google Scholar
• DardirMDFerransVJMikhaelYSCardiac morphologic and functional changes induced by epirubicin chemotherapyJ Clin Oncol1989779479582738625
   PubMed Web of Science ®Google Scholar
• SpeyerJLGreenMDKramerEProtective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancerN Engl J Med19883197457523137469
   PubMed Web of Science ®Google Scholar
• SpeyerJLGreenMDZeleniuch-JacquotteAICRF-187 permits longer treatment with doxorubicin in women with breast cancerJ Clin Oncol1992101171271727913
   PubMed Web of Science ®Google Scholar
• FeldmannJEJonesSEWeisbergSRAdvanced small cell lung cancer treated with CAV (cyclophosphamide + Adriamycin® + vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR-529, ICRF-187, Zinecard®)Proc Ann Meet Am Soc Clin Oncol199211AA93
   Google Scholar
• VenturiniMMichelottiADel MastroLMulticenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancerJ Clin Oncol199614311231208955656
   PubMed Web of Science ®Google Scholar
• WexlerLHAndrichMPVenzonDRandomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicinJ Clin Oncol1996143623728636745
   PubMed Web of Science ®Google Scholar
• SwainSMWhaleyFSGerberMCEwerMSBianchineJRGamsRADelayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapyJ Clin Oncol1997154133313409193324
   PubMed Web of Science ®Google Scholar
• SwainSMWhaleyFSGerberMCCardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancerJ Clin Oncol199715131813329193323
   PubMed Web of Science ®Google Scholar
• LopezMViciPDi LauroKRandomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomasJ Clin Oncol19981686929440727
   PubMed Web of Science ®Google Scholar
• LipshultzSERifaiNDaltonVMThe effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemiaN Engl J Med200435114515315247354
   PubMed Web of Science ®Google Scholar
• HensleyMLHagertyKLKewalramaniTAmerican Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectantsJ Clin Oncol200927112714519018081
   PubMed Web of Science ®Google Scholar
• MartyMEspiéMLlombartAMonnierARapoportBLStahalovaVDexrazoxane Study GroupMulticenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapyAnn Oncol200617461462216423847
   PubMed Web of Science ®Google Scholar
• SeymourLBramwellVMoranLAUse of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site GroupCancer Prev Control1999314515910474762
   PubMedGoogle Scholar
• KalamKMarwickTHRole of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysisEur J Cancer2013492900290923706982
   PubMed Web of Science ®Google Scholar
• SepeDMGinsbergJPBalisFMDexrazoxane as a cardioprotectant in children receiving anthracyclinesOncologist2010151220122621051660
   PubMed Web of Science ®Google Scholar
• LangerSWSehestedMJensenPBAnthracycline extravasation: a comprehensive review of experimental and clinical treatmentsTumori200995327328219688963
   PubMed Web of Science ®Google Scholar
• SonneveldPWassenaarHANooterKLong persistence of doxorubicin in human skin after extravasationCancer Treat Rep19846868958966733702
   PubMedGoogle Scholar
• ReillyJJNeifeldJPRosenbergSAClinical course and management of accidental adriamycin extravasationCancer197740520532056922655
   PubMed Web of Science ®Google Scholar
• MayoDJPearsonDCChemotherapy extravasation: a consequence of fibrin sheath formation around venous access devicesOncol Nurs Forum19952246756807675669
   PubMedGoogle Scholar
• LaughlinRALandeenJMHabalMBThe management of inadvertent subcutaneous adriamycin infiltrationAm J Surg1979137408412373478
   PubMed Web of Science ®Google Scholar
• PreussPPartoftSCytostatic extravasationsAnn Plast Surg19871943233293688779
   PubMed Web of Science ®Google Scholar
• LinderRMUptonJOsteenRManagement of extensive doxorubicin hydrochloride extravasation injuriesJ Hand Surg Am19838132386827049
   PubMed Web of Science ®Google Scholar
• RudolphRSteinRSPattilloRSkin ulcers due to adriamycinCancer19763810871094953958
   PubMed Web of Science ®Google Scholar
• MouridsenHTLangerSWButerJTreatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studiesAnn Oncol200718354655017185744
   PubMed Web of Science ®Google Scholar
• LangerSWSehestedMJensenPBButerJGiacconeGDexrazoxane in anthracycline extravasationJ Clin Oncol20001816306410944144
   PubMed Web of Science ®Google Scholar
• JensenJNLock-AndersenJLangerSWMejerJDexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclinesScand J Plast Reconstr Surg Hand Surg200337317417512841619
   PubMed Web of Science ®Google Scholar
• El-SaghirNOtrockZMufarrijADexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healingLancet Oncol20045532032115120669
   PubMed Web of Science ®Google Scholar
• BosAMvan der GraafWTWillemsePHA new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxaneActa Oncol200140454154211504316
   PubMed Web of Science ®Google Scholar
• MouridsenHTLangerSWTjoernelundJAnthracycline extravasation in breast cancer patients. Effective treatment with dexrazoxane in three multicenter trialsEuropean J Cancer (Suppl)200867197
   Web of Science ®Google Scholar
• MuthuramalingamSGaleJBradburyJDexrazoxane efficacy for anthracycline extravasation: use in UK clinical practiceInt J Clin Pract201367324424923409691
   PubMed Web of Science ®Google Scholar
• FontaineCNoensLPierrePDe GrèveJSavene® (dexrazoxane) use in clinical practiceSupport Care Cancer20122051109111222278308
   PubMed Web of Science ®Google Scholar
• JordanKBehlendorfTMuellerFSchmollHJAnthracycline extravasation injuries: management with dexrazoxaneTher Clin Risk Manag20095236136619536310
   PubMedGoogle Scholar
• HünerlitürkoglouANTapprichCLangerSWSehestedMJensenPBHeintgesTSuccessful use of dexrazoxane in two cases of anthracycline containing polychemotherapyEuropean J Clin Med Oncology2009111315
   Google Scholar
• LangerSWTreatment of anthracycline extravasation from centrally inserted venous cathetersOncol Rev20082115117
   Google Scholar
• HolcenbergJSTutschKDEarhartRHPhase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adultsCancer Treat Rep19867067037093089595
   PubMedGoogle Scholar
• KoellerJMEarhartRHDavisHLPhase I trial of ICRF-187 by 48-hour continuous infusionCancer Treat Rep1981655–64594636786740
   PubMedGoogle Scholar
• LiesmannJBeltRHaasCHoogstratenBPhase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancyCancer1981478195919626784914
   PubMed Web of Science ®Google Scholar
• Von HoffDDHowserDLewisBJHolcenbergJWeissRBYoungRCPhase I study of ICRF-187 using a daily for 3 days scheduleCancer Treat Rep1981653–42492526786738
   PubMedGoogle Scholar
• VogelCLGorowskiEDavilaEPhase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumorsInvest New Drugs1987521871983115912
   PubMed Web of Science ®Google Scholar
• SalzerWLDevidasMCarrollWLLong-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children’s oncology groupLeukemia20102435537020016527
   PubMed Web of Science ®Google Scholar
• TebbiCKLondonWBFriedmanDDexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s diseaseJ Clin Oncol20072549350017290056
   PubMed Web of Science ®Google Scholar
• KoppLMBernsteinMLSchwartzCLThe effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS)J Clin Oncol201230Suppl abstr 9503
   Google Scholar
• BarryEVVroomanLMDahlbergSEAbsence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxaneJ Clin Oncol20082671106111118309945
   PubMed Web of Science ®Google Scholar